Growth masking margin squeeze; recovery unproven
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Reaffirmed capex Rs350 Cr, maintained medical/EV timelines. But PAT -3% YoY despite revenue +17% signals execution lag vs. bullish tone.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Solid 17% revenue growth on engineering volume momentum, but consolidated PAT down 3% YoY signals margin recovery lagging. Management confident on steel price passthrough and new business ramps (medical 20%, EV breakeven FY27-28, CDMO FY28) but execution risk remains high: Q1 already showed PBIT flat in engineering despite strong volumes, Shanthi Gears profit crashed 55%, cell constraints expected 2-3 more quarters.
₹6215.3 Cr
Revenue · +17.1% YoY₹294 Cr
Reported PAT · −3% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Engineering volume growth 17% with strong momentum
OVERSTATEDVolume 17% confirmed; PBIT Rs153 Cr flat YoY despite volume growth
EV business behind peak losses with highest ever turnover
OVERSTATEDRevenue Rs250 Cr (up 26% YoY) with PBIT Rs9 Cr; segment still loss-making per call
Medical 20% revenue growth with profitability continuation
UnverifiedMedical part of Others segment (Rs256 Cr, +8.5% YoY); specific medical growth unverified at call level
Full recovery of steel inflation losses including Q1 in coming quarters
MISSQ1 OPM 8.8%, consolidated PAT down 3% YoY; recovery timing unproven
Double-digit EBIT margin growth going forward
PartialNo specific margin guidance given; avoided quantifying Q1 underrecovery
Earnings quality
What changed since the last call
Capex: reaffirmed Rs350 Cr
MaintainedPrior guidance 300-350 Cr; now Rs350 Cr confirmed for FY27. No upgrade, upper band locked.
Medical growth: 20% confirmed
MaintainedPrior: 15-20% YoY medical growth guidance. Current: 20% growth in surgical core business reaffirmed. Others segment (inclusive) grew 8.5%, so specific medical outperformance claimed.
EV loss profile: improving visibility
UpgradeQ1 showed 64% loss reduction vs Q4, PBIT Rs9 Cr positive; one business to breakeven FY27, two in FY28 (vs. prior vague timeline).
Margin recovery: delayed confirmation
NeutralCall claimed full steel recovery + margin neutralization in coming quarters; but delayed quantifying Q1 underrecovery, suggesting lag longer than expected.
Export momentum: double-digit growth
UpgradeConfirmed >10% export growth in Q1; 14% of consolidated revenue; new Nepal EV exports (100+ units shipped).
MFP outlook: weakened
DowngradeMFP PBIT down 24% YoY despite 11.5% revenue growth; Greenfield delay by 6 months; Hyundai drag continuing.
The Q&A
Analysts pressed hard on margin compression (Joseph George, Salil Desai, Anupam Gupta); management held guidance but deflected on quantifying Q1 underrecovery and concrete margin recovery timelines. Joseph George asked for specific recovery amount — Ahuja refused. Salil Desai probed whether recovery includes cumulative Q1 loss — Ahuja confirmed yes for steel only. No evasion, but lack of specificity weakened credibility on near-term recovery.
Margin pressure Q1 — Joseph George, IIFL Capital
PartialSteel price increase lagged by 2-3 quarters; confident full recovery will happen; margin neutralization in coming quarters.
Quantified underrecovery — Joseph George, IIFL Capital
DodgedDeclined to give number; said will grow EBIT margin in double digit post-price recovery.
Cumulative margin recovery — Salil Desai, Marcellus
AnsweredFor steel prices, including Q1, we will recover fully.
Medical 3-5x growth claim — Devesh Kayal, Boring AMC
PartialCore surgical 20% YoY growth with profitability; new Medicura acquisition will take time on margins. Confident double-digit growth continues.
CDMO/3xper timeline — Devesh Kayal, Boring AMC
AnsweredCommissioning done; clean room 30-40 days; inspection FY28; 15 customers working with us at semi-commercial; on track for revised projections.
MFP segment weakness — Salil Desai, Marcellus
AnsweredVolume-led growth; railways still a drag; Hyundai weak; Greenfield delayed 6 months; price recovery yet to come.
EV loss reduction drivers — Salil Desai, Marcellus
AnsweredAll four businesses seeing traction; volumes strong (HCV, SCV highest ever, 3W up 64% from Q4); margins improving despite commodity headwinds; no one-off.
EV peak losses — Prithvi Raj Earle, Unifi
AnsweredDirectionally yes; volumes increasing QoQ so beyond peak losses now.
EV breakeven timeline — Prithvi Raj Earle, Unifi
AnsweredVaries by business. One business breakeven FY27, two in FY28.
Engineering volume growth — Prithvi Raj Earle, Unifi
AnsweredVolume grew about 17%.
EV 3W wholesale vs Vahan lag — Joseph George, IIFL Capital
Answered30-45 day lag between billing and Vahan; over 3-6 months they match; last year billing 6,700 vs Vahan 6,500.
Subsidiary investment plan FY27 — Joseph George, IIFL Capital
AnsweredRs250 Cr already infused Q4; Rs250 Cr more in Q3; total Rs750 Cr guidance over period.
Non-steel inflation recovery — Anupam Gupta, HDFC
PartialFirst time seeing this quantum; taken up with customers; in discussions; hopeful majority recoverable.
Cycles business recovery — Anupam Gupta, HDFC
AnsweredQ1 strong for cycles (schools/colleges opening); improved share; targeting at least 2 basis point margin improvement over year.
Orange Koi business plan — Anupam Gupta, HDFC
AnsweredPart of Others. Small startup acquisition for metal injection molding (additive manufacturing). Will study market for 1-2 quarters before scaling guidance.
Jayem EV losses despite growth — Salil Desai, Marcellus
AnsweredHeadwinds in design/development core business; diversifying into battery manufacturing (high potential); battery assembly line set up FY27; outlook positive for top/bottom line.
Capex excluding CG Power — Salil Desai, Marcellus
AnsweredTI Rs350 Cr, Shanthi Gear Rs100 Cr. Going to engineering, MFP, TI Medical, 3xper CDMO. Group ex-CG Rs600-700 Cr total.
TI Clean Mobility investor conversion — Ketan Sanghvi
AnsweredConversion at IPO only. No fixed IPO timeline. Depends on market conditions, profitability, revenue. Stake decided by valuation at that time.
Export momentum engineering — Prithvi Raj Earle, Unifi
AnsweredNext 1-2 quarters bullish. Exports >10% growth (double digit); 14% of TI revenue; momentum to continue unless geopolitical hurdles.
Nepal EV exports — Harshvardhan Kothari
Answered100+ units shipped/in process; initial feedback very positive; bullish on Nepal market; also exploring Africa (Tanzania/Ethiopia) exploratory stage.
Cell supply bottleneck — Harshvardhan Kothari
PartialGenuine challenge Q1+. Chinese tax exemptions lifting in 2-3 quarters will bring prices down; but BESS demand high, so prices not cooling Q1/Q3. Mitigating: pre-booking, locking prices with suppliers.
Tipper order book HCV — Harshvardhan Kothari
AnsweredIntroduced Q1 (28-ton); market shifting to 35-ton+. 20-25 tippers sold; feedback positive. Market seeding while serving existing order book (4x2 tractor trailer confirmed orders).
Port HCV deployments — Harshvardhan Kothari
AnsweredWelspun Anjar: 22 trucks deployed; Vizag/Chennai single digits; Wonder Cement: 2 ports (Tuna, Dahej). Other ports in discussions.
L3 autos rollout — Harshvardhan Kothari
AnsweredIntroduced Q1 in select UP/Bihar markets (partial seeding/testing). Feedback pending before full rollout decision.
NCR EV policy traction — Harshvardhan Kothari
AnsweredYes, seeing traction. Mandatory phase in couple months will drive huge demand. Ramping dealer appointments, secondary footprints in NCR.
Guidance
Engineering strong momentum next 1-2 quarters
MediumQ1 volume +17%; demand bullish across segments except Hyundai; geopolitical risk flagged
Medical 20% YoY revenue growth with profitability
MediumCore surgical confirmed 20%; Medicura acquisition will weigh on margins initially
EV revenue growth via volume traction
MediumAll 4 businesses seeing volumes; Q1 Rs240 Cr highest-ever; NCR policy mandatory Sep 2026 will drive demand
EBIT margin double-digit improvement post-price recovery
LowNo baseline or target number; steel recovery 2-3 quarters lag; non-steel inflation ongoing discussions
Cycles margin target at least 2bp improvement
MediumAiming for ~5 percentage point margins over FY27; Q1 benefited from school/college openings
EV margin recovery on volume ramp
MediumOne business FY27 breakeven, two in FY28; still loss-making overall despite Q1 improvement
TI standalone Rs350 Cr capex FY27
HighConfirmed; going to engineering, MFP, medical, CDMO; prior range 300-350 Cr
Shanthi Gear Rs100 Cr capex FY27
HighStated explicitly; subsidiary expansion
Group ex-CG Power capex Rs600-700 Cr
MediumTotal inclusive of TI, Shanthi Gear, subsidiaries; includes medical, EV, CDMO ramp
Risks the call surfaced
Margin recovery execution
HighQ1 PBIT flat in engineering (+20% volume) suggests pricing headroom limited. Customers may resist price increases. Non-steel inflation (fuel, freight) also under negotiation with uncertain outcomes.
Subsidiary underperformance
MediumShanthi Gears PBT down 55% YoY (Rs14 Cr vs Rs31 Cr) on same revenue base (slight decline). Drags consolidated ROIC despite strong engineering. CG Power offset by Shanthi weakness.
MFP segment weakness
MediumMFP PBIT Rs28 Cr (-24% YoY) on 11.5% revenue growth. Railways segment dragging; Hyundai (specific customer) not performing; Greenfield expansion delayed 6 months (capacity lag).
EV breakeven uncertainty
MediumEV business still loss-making overall (PBIT Rs9 Cr standalone but larger losses in subsidiaries Jayem, TI Clean Mobility). Breakeven claims (one FY27, two FY28) are directional not quantified. Cell supply constraints expected 2-3 more quarters.
New business gestation (CDMO, Medical)
Medium3xper CDMO inspection FY28 (not FY27); commercial ramp post-inspection uncertain. TI Medical Medicura margins will be depressed 1-2 years. Both capex-heavy with delayed ROIC.
Management
Score 6/10. Candid on challenges (Hyundai, railways, Shanthi Gears, cell constraints) but vague on margin recovery timing/quantum. Deflected on quantifying Q1 underrecovery. Confident tone on long-term but wavering on near-term execution. Mixed: Volume growth 17% delivered; export >10% delivered. But PBIT flat in engineering, Shanthi down 55%, margin recovery lagging 2-3 quarters. PAT -3% despite revenue +17% signals execution shortfall vs. guidance tone.
1 · Q2-Q3 FY27
Steel price passthrough to customers; margin neutralization expected
2 · Q2 FY27
TI Medical IV cannula facility commissioning; revenue from Medicura acquisition
3 · Q3 FY27
Rs250 Cr subsidiary investment second tranche; capex deployment acceleration
Management confident on steel price passthrough and new business ramps (medical 20%, EV breakeven FY27-28, CDMO FY28) but execution risk remains high: Q1 already showed PBIT flat in engineering despite strong volumes, Shanthi Gears profit crashed 55%, cell constraints expected 2-3 more quarters.
TII Q1 FY27: PAT dips 3% YoY to ₹294 Cr on EV/chip losses despite 17% revenue growth
PAT -3.05% YoY · revenue +17.07% · margins compressing
₹6,215.33 Cr
+17.07% YoY
₹293.96 Cr
-3.05% YoY
4.65%
-1pp YoY
₹8.71
Tube Investments of India reported consolidated revenue of ₹6,215 Cr for Q1 FY27 (quarter ended June 30, 2026), up 17.1% YoY from ₹5,309 Cr, but PAT fell 3.1% YoY to ₹294 Cr from ₹303 Cr. Revenue was essentially flat QoQ against ₹6,215 Cr in Q4 FY26, while PAT rose 25.6% QoQ from ₹234 Cr — a low-base sequential recovery rather than a fresh trend, so the YoY comparison is the one that matters. Standalone (secondary basis): revenue ₹2,366 Cr +17.9% YoY, PAT ₹159 Cr -5.6% YoY, EPS ₹8.19 versus ₹8.69. Neither period carried exceptional items on either basis, so no adjustment is needed — the decline is on a like-for-like basis.
Q1 FY-2027 vs prior quarters
The miss is below the line, not on operations: consolidated PBT actually rose 2.6% YoY to ₹461 Cr from ₹449 Cr. The effective tax rate climbed to 36.2% from 32.5% YoY, pulling net profit margin down to 4.6% from 5.6% and operating margin to roughly 8.8% from roughly 10.3%. Within segments, Power Systems (CG Power's core power-equipment business) profit jumped 44.5% YoY to ₹322 Cr, and CG Power's overall PBT — spanning its Power Systems, Industrial Systems and Semiconductor units — grew about 16% YoY to ₹423 Cr per the company's press release. That strength was offset by widening losses at Electric Vehicles (₹147 Cr loss versus ₹136 Cr YoY) and Semiconductors (₹50 Cr loss versus ₹9 Cr YoY), plus a weaker Gears and Gear Products segment (₹14 Cr versus ₹31 Cr YoY) — Shanthi Gears' own revenue (₹115 Cr vs ₹135 Cr) and PBT (₹14 Cr vs ₹31 Cr) both fell YoY per the release.
The stock went into the print at ₹2,721.9, down 7.2% over the past month of trading.
For context: revenue is at a 6-quarter high.
Management projects a bullish outlook for its core engineering business, anticipating strong volume growth despite short-term margin pressures from inflation, which it plans to pass through with a lag. The company guides for FY27 standalone capex of Rs. 300-350 crores and an additional ~Rs. 300 crores of investment int
— This quarter: met
Management's Q4 FY26 guidance flagged "strong volume growth despite short-term margin pressures" for the engineering business — both played out almost exactly as described, so this quarter reads as "met" against that framing rather than a beat or miss. Medical devices revenue grew 23.3% YoY to ₹58.6 Cr, ahead of the 15-20% YoY growth range management guided for FY27. The EV business, which management said would scale after resolving supply issues, instead posted a wider loss — that initiative is running behind plan. No reliable street/consensus estimate specific to this quarter could be sourced, so vsStreet is marked unknown. During the quarter TII completed its planned acquisition of 76.24% of Orange Koi Private Limited for ₹35 Cr (a medical/defence precision-parts manufacturer, consolidated from April 6, 2026, accounted on provisional fair values) and put a further ₹25 Cr into 3xper Innoventure's preference shares; separately, one of the group's subsidiaries saw its auditors resign during the quarter per company disclosures, unrelated to this result's numbers.
W1
Electric Vehicles segment loss (₹147 Cr this quarter vs ₹136 Cr YoY) — whether it narrows as management's post-supply-issue scale-up plan progresses
W2
Semiconductors segment loss (₹50 Cr this quarter vs ₹9 Cr YoY) — a sharp deterioration to track for stabilization
W3
Effective tax rate (36.2% this quarter vs 32.5% YoY) — normalization here would be the single biggest lever for margin recovery
No exceptional items in current or year-ago quarter (either basis), so YoY PAT comparison is clean/like-for-like; consolidated Total Income (6,327.10) is ₹0.20 Cr off the sum of its components, an immaterial rounding artifact in the source filing; consolidated PAT includes ₹Nil discontinued-ops contribution this quarter (vs ₹1.95 Cr in FY26 full year).
Margin Watch Ahead: What Tube Investments Needs to Prove in Q1
Street expects steady earnings on Auto & EV momentum, but margin compression in FY26 and auditor transitions set up a tighter scrutiny on execution.
The Number That Matters: Margins
Tube Investments traded most of FY26 on earnings stability and a clean dividend (₹1.50, just paid). But profit margin compression—from 3.6% to 2.9% year-over-year—is the elephant in the room. Q1 FY-2027 will tell us whether this was cyclical (commodity/RM cost pressures, CapEx drag) or structural (market share loss, pricing power erosion in auto components). Revenue growth in the 8-12% range would be on plan; what matters is whether OPM holds steady or shrinks further.
~₹5,400 Cr
Tracking FY26 Q1 (₹5,380 Cr); mid-single-digit growth on auto production recovery
~₹300 Cr
On par with FY26 Q1 (₹303 Cr); dependent on margin hold
2.8–3.2%
Guidance: recovery vs further compression signals CapEx payoff or headwinds
A strong quarter would show OPM recovery toward 3.2%+ and net profit ₹310+ Cr, signalling CapEx leverage and better input costs. A weak quarter would see OPM fall below 2.8% or net profit contract YoY—a red flag for execution or market share loss.
On Track for Full-Year Guidance?
TII management has not published explicit FY-2027 guidance as of our last data refresh. However, based on the FY26 trajectory (EPS ₹32.81, down from ₹34.83 in FY25 despite 17% revenue growth), the market is pricing in low-single-digit profit growth. Q1 will either confirm this cautious view or hint at margin recovery in H2. The Auto & EV index has stabilized after a sharp May-June sell-off; TII's Q1 execution could reset sentiment on the sector's capital intensity.
What the Street Says
1 · Auditor Transition (Jun 29–Jul 30)
Outgoing auditor M/s. Sundaram & Srinivasan resigned as statutory auditors of subsidiary TI Clean Mobility Private Limited; Price Waterhouse recommended as new group auditor for FY27 onwards. No audit qualifications flagged—routine transition for a growing subsidiary portfolio.
2 · 3xper Innoventure Investment (Apr 23)
TII committed additional ₹75 Cr to EV startup 3xper Innoventure, bringing total investment to ₹100 Cr. Signals aggressive capital deployment into the EV ecosystem; capital burn & path to profitability will matter for consolidated opex.
3 · Dividend Paid (Aug 7)
₹1.50 per share final dividend for FY26 paid on schedule. Unchanged from prior year—signals stable cash generation despite margin pressure. Payout ratio ~4.6% of FY26 EPS.
What to Watch on Result Day (Aug 14)
1. OPM trajectory & CapEx commentary: Is management seeing margin recovery or further pressure? Any guidance on FY27 CapEx intensity? 2. Auto volumes & EV mix: How are TII's key auto customers (two-wheeler, commercial vehicle) performing? EV exposure trending up? 3. 3xper & subsidiary margins: How much drag from the startup ecosystem? Any path to breakeven articulated? 4. Sector tailwinds vs headwinds: Input costs normalizing? Pricing power returning in H2?
Tube Investments enters Q1 results with steady revenue momentum but margin anxiety. The Street is constructive on 3–5 year EV upside, but Q1 will test whether near-term capital intensity is already pricing in. A flat-to-better OPM print resets confidence; margin compression below 2.8% re-rates risk premium upward. Board convenes Aug 14 to approve unaudited results; earnings call follows Aug 17.
17% Revenue Growth Masks Profit Decline; Margin Recovery Unproven
Volume traction is real, but consolidated PAT fell 3% YoY despite 17% revenue growth. Management confident on steel price passthrough, but timing vague and Q1 underrecovery unquantified—the central bet for FY27 remains unproven.
₹6,215 Cr
+17.1% YoY
₹294 Cr
−3.0% YoY
8.8%
compressed YoY
₹153 Cr
flat YoY despite +20% volume
The quarter delivered strong top-line growth—revenue up 17%, engineering volumes +17%, export momentum >10%—yet consolidated profit fell 3% YoY. This is the central tension: growth without earnings leverage. The culprit is stark: engineering PBIT of ₹153 Cr is flat year-on-year despite a 20% volume surge. On the call, management attributed this to a 2–3 quarter lag in recovering steel price inflation and blamed non-steel cost headwinds (fuel, freight from West Asia geopolitics). But the fact that pricing power remained flat in a rising-volume quarter raises credibility questions about full recovery odds.
Why profit lagged growth
Shanthi Gears' profit collapse—down ₹17 crore or 55% YoY—is particularly acute. Metal Formed Products PBIT fell 24% despite 11.5% revenue growth, dragged by railways (a named weak customer) and Hyundai (also explicitly weak per management). A Greenfield plant expansion was delayed 6 months, compounding capacity constraints. These are not transient headwinds; they signal structural pressure on both pricing and customer demand within the materials segment. The OPM of 8.8% (vs. prior-year comparables) confirms that inflation is real, recovery is lagging, and margin expansion from here depends entirely on execution of the passthrough strategy.
Management claims vs. what holds up
"Engineering volume growth 17% with strong momentum"
Volume +17% confirmed; PBIT flat YoY despite volume growth → Overstated on momentum
"EV business behind peak losses with highest-ever turnover"
Q1 revenue ₹250 Cr (highest-ever) but segment still loss-making overall → Overstated
"Medical 20% revenue growth with profitability"
Specific medical growth unverified at call; Others segment (inclusive) grew only 8.5% → Unverified
"Full recovery of steel inflation losses in coming quarters"
Q1 OPM 8.8%, PAT −3% YoY; recovery timing unproven. Management avoided quantifying Q1 underrecovery → Contradicted
"Double-digit EBIT margin improvement going forward"
No baseline or target number; vague on timing → Partial
Analysts pressed hard on margin recovery—Joseph George (IIFL Capital) asked for a specific quantified amount of Q1 underrecovery; MD Mukesh Ahuja declined to provide a number. Salil Desai (Marcellus) probed whether cumulative Q1 losses would be fully recovered; Ahuja confirmed yes for steel but deflected on non-steel inflation. This lack of specificity, combined with PBIT flatness in a rising-volume quarter, weakened credibility on near-term recovery claims. Management's tone remained confident, but the data suggests either greater uncertainty than acknowledged or a lag longer than the guided 2–3 quarters.
What changed on this call
Capex reaffirmed at ₹350 Cr (TI standalone) — no upgrade from the prior 300–350 Cr range; upper band confirmed. Group capex ex-CG Power targeting ₹600–700 Cr. Medical surgical core growth locked at 20% YoY — unchanged from prior guidance but specific to surgical business (the broader Others segment grew only 8.5%, so medical outperformance is implied). EV breakeven milestones now explicit — one business FY27, two in FY28 (prior calls were vaguer). Margin recovery timeline remained vague — promised double-digit EBIT improvement post-passthrough but no baseline or target number disclosed. MFP weakened — PBIT down 24% despite 11.5% revenue growth, with no recovery plan articulated for railways or Hyundai drag. Export momentum confirmed at >10% YoY — double-digit growth; 14% of consolidated revenue; Nepal EV exports 100+ units shipped (first market entry).
Bull and bear ledger
Engineering volume +17%; strong momentum across segments
Export growth >10% (14% of revenue); new markets (Nepal, Africa exploratory)
EV loss reduction ~₹40–50 Cr vs. Q4; all four businesses seeing volumes
Medical surgical core 20% growth reaffirmed; Medicura acquisition ramping
Capex ₹350 Cr (TI) + ₹100 Cr (Shanthi Gear) confirms growth investment
ROIC annualized 41% (vs. 39% prior year) despite margin compression
Consolidated PAT −3% YoY despite 17% revenue growth
Engineering PBIT flat despite 20% volume growth (pricing power unproven)
Shanthi Gears profit down 55% YoY (₹31 Cr → ₹14 Cr); no recovery plan
MFP PBIT down 24% despite 11.5% revenue growth (railways, Hyundai drag)
Management declined to quantify Q1 underrecovery (credibility dent)
Non-steel inflation (fuel, freight, West Asia) unquantified and unproven on recovery
EV still loss-making overall (PBIT Rs9 Cr in TI, larger losses in subsidiaries)
FII flows negative YoY (down from 26.31% to 22.34%); institutional trim underway
Risks, ranked by holder concern
1. Margin recovery execution
HIGHQ1 PBIT flat in engineering (+20% volume) signals pricing headroom may be limited. Customers may resist 2–3 quarter lag on price recovery. Non-steel inflation (fuel, freight) also under discussion with uncertain outcomes. If recovery stalls, consolidated margin re-rating is off the table.
2. Subsidiary underperformance
HIGHShanthi Gears profit crashed 55% YoY (₹31 Cr → ₹14 Cr) on same/declining revenue. Drags consolidated ROIC and capex ROI. FY27 capex (₹100 Cr) assumes recovery; no plan articulated on call.
3. MFP segment weakness
MEDIUMPBIT down 24% despite 11.5% revenue growth. Railways (named drag) and Hyundai (named as weak) show customer/segment-specific risk. Greenfield delayed 6 months compounds capacity lag. Timing of recovery unclear.
4. EV breakeven timing
MEDIUMEV still loss-making overall (subsidiary Jayem, TI Clean Mobility in red). Breakeven claims (one FY27, two FY28) are directional, not quantified. Cell supply bottleneck expected 2–3 more quarters; Chinese tax exemptions lifting could help but not guaranteed.
5. New business gestation risk
MEDIUM3xper CDMO inspection deferred to FY28 (not FY27); commercial ramp post-inspection uncertain. TI Medical Medicura margins depressed 1–2 years. Both capex-heavy with delayed ROIC payback.
6. Export geopolitical risk
MEDIUMExports 14% of consolidated revenue; >10% YoY growth acknowledged as bullish. But West Asia crisis (fuel, freight) and trade tensions represent unquantified downside to near-term momentum.
How the street is positioned
Price reaction — modest recovery story. Q1 result announced Friday, Aug 14, 2026 at pre-market close ₹2,733.50. Day-1 pop +0.29% (modest); day-3 rebound +8.32%. The recovery held, confirming market acknowledgment of growth momentum, but the muted initial move (vs. the 17% revenue growth headline) signaled investor caution on profitability lag and margin recovery timing. At ₹2,930 today (Aug 20, 2026), the stock sits −12.15% off its all-time high of ₹3,335.20 and +35.34% off the 52-week low of ₹2,164.90. Price is above the 20-day SMA (₹2,801.65) and 200-day SMA (₹2,775.56) but below the 50-day (₹2,946.73), suggesting minor pullback after a run but not a structural break. RSI 64 is neutral, not overbought. Volume trend is increasing—institutional accumulation, not distribution, on the price dip.
Institutional flows — FII trimming. Latest FII stake is 22.34% (Q1 FY27) vs. 26.31% a year ago (Q1 FY26), a decline of 397 basis points. DII stake is 21.02% (flat vs. Q4 20.75% post-adjustment for dilution). Promoter 43.93% (slightly down from 44.09% YoY). QoQ, FII added 92 bp (22.34% vs. 21.42% in Q4), suggesting some stabilization post-results, but the structural downtrend remains intact: FII bought into the 2025 growth story but are trimming on execution lag and vague margin recovery guidance. This is not panic, but it is caution. Institutional conviction is withering.
Valuation context. At ₹2,930, TII trades ~12.5x annualized FY27 PAT (assuming ₹234 Cr quarterly normalized PAT, which is below Q1 ₹294 Cr—signaling margin compression expectation baked into price). The −12% drawdown from ATH is modest for a stock facing margin recovery uncertainty; it reflects limited de-rating risk but also limited upside enthusiasm until execution is proven. The stock is not cheap but is fairly valued for a Hold—a fair price for a mature auto-tier-1 with mid-teens long-term growth visibility but near-term execution risk.
What to watch next
1 · Q2 FY27 margin recovery (2–3 months)
Steel price passthrough should begin to flow through OPM. Target: engineering PBIT >₹165 Cr (breakeven to modest growth vs. ₹153 Cr Q1) and consolidated OPM ≥9.5%. Miss = margin recovery is slower or shallower than guided; a step down in conviction.
2 · Medical/Medicura ramp and 3xper CDMO customer traction (Q2-Q3)
TI Medical cannula facility commissioning Q2; revenue start Aug–Sep 2026. CDMO clean room finishing 30–40 days (post-call); 15 customers active at semi-commercial. Target: Others segment PBIT contribution >₹20 Cr by Q2, proving medical outperformance vs. aggregate +8.5% growth. Miss = margin dilution from integrations; new business upside is lower.
3 · EV breakeven milestone (FY27-28)
One EV business to breakeven FY27 (by Mar 2027), two in FY28. NCR Commercial Vehicle policy mandatory phase-in Sep 2026 (next quarter) should drive demand surge in 3W/SCV. Target: TI Clean Mobility or Jayem EBIT turns positive by Q3 FY27. Miss = timeline slips, cell constraints persist, or volumes don't convert to margin.
4 · Shanthi Gears recovery trajectory (Q2-Q3)
Profit crashed 55% YoY in Q1; capex ₹100 Cr planned for FY27. Target: Shanthi PBT stabilizes at ≥₹18 Cr in Q2 (flat vs. ₹14 Cr Q1) and >₹25 Cr by Q3 (half of pre-collapse ₹31 Cr). Miss = capex doesn't translate to ROIC; subsidiary destruction of shareholder value continues.
The bottom line
Tube Investments delivered a solid but messy quarter. Revenue grew 17%, engineering volumes +17%, exports >10%—the growth momentum is real and geographically diversified. But consolidated PAT fell 3% YoY, engineering PBIT was flat despite volume surge, and Shanthi Gears profit collapsed 55%. This is a classic margin squeeze: inflation lagged, pricing power unproven, and subsidiary execution faltering.
Management remains confident on full steel price recovery in 2–3 quarters and double-digit EBIT margin improvement thereafter, but deflected on quantifying Q1 underrecovery and offered no recovery baseline. For a company that guided for this scenario six months ago, the lack of specificity now is a credibility dent. The institutional sector (FII down 397 bp YoY) appears skeptical of near-term recovery timing.
Rating: Hold. Confidence: 6/10. The bull case (margin recovery + medical/CDMO upside + EV breakeven FY27-28) is credible if execution holds—and if it does, PAT could re-accelerate to 15%+ growth by FY28, justifying a re-rating to 14–15x PE. The bear case (margin lag persists, subsidiary drag continues, EV timing slips) is equally plausible given Q1 evidence. The stock at ₹2,930 is fairly valued for the ambiguity—not cheap, not expensive. The single number to track from here is consolidated OPM in Q2: if it breaks 9%+ (vs. Q1 8.8%), margin recovery is credible; if it stalls, the FY27 story unravels.